Biosimilar earnings were due in large part to the European launches of biosimilar trastuzumab (Kanjinti) and biosimilar adalimumab (Amgevita), which Amgen said are progressing in line with expectations and annualizing at more than $300 million.
Amgen said last week that its biosimilars business generated $82 million in sales in the second quarter of the year. That number represents total growth of 49% over the previous quarter.
Those earnings were due in large part to the European launches of biosimilar trastuzumab (Kanjinti) and biosimilar adalimumab (Amgevita), which Amgen said are progressing in line with expectations and annualizing at more than $300 million. Kanjinti recently also launched in the United States, along with biosimilar bevacizumab, Mvasi.
However, in addition to making strides with its own biosimilars, Amgen faces competition for market share from other drug makers’ biosimilars of its innovator products. Brand-name Neulasta, Amgen’s innovator pegfilgrastim product, exited the second quarter with 80% of the market share for long-acting pegfilgrastim, a scenario that it said reflects a competitive biosimilars market.
In the company's earnings call, Muro Gordon, Amgen’s head of commercial operations, said, “We are seeing an uptick of biosimilars in the 340B channel. We're also seeing a stronger performance of biosimilars in business that we have not contracted.” He later added that, since the market entry of the second biosimilar pegfilgrastim (Coherus BioScience’s Udenyca, following Mylan and Biocon’s earlier Fulphila), Amgen has seen more volume erosion and price erosion for its brand-name product.
Internationally, sales of Neulasta declined by 31% due to competition. However, Amgen’s sales of the Onpro presentation of the product, which delivers pegfilgrastim via an on-body injector, were stable quarter over quarter. In the future, said Gordon, “we may see some price pressure on Onpro.”
Looking to the next steps for its own biosimilars business, Amgen indicated that it expects phase 3 data from a study in patients with non-Hodgkin lymphoma for its biosimilar rituximab candidate, ABP 798, during the current quarter. The company, together with partner Allergan, previously announced positive topline results for the product in a combined phase 1 and phase 3 study of the proposed biosimilar in patients with rheumatoid arthritis.
It also expects the FDA to make its regulatory decision on ABP 710, a proposed biosimilar infliximab, in December of this year. The company recently informed the European Medicines Agency that it will not pursue approval in Europe, however, following a change in its strategy for the European market.
Finally, as he closed the earnings call, Amgen’s chairman and chief executive officer, Bob Bradway, hinted that the company had “the prospect of branded biosimilars” in the future. Branded biosimilars, a product strategy that is also apparently being explored by Eli Lilly and Company, could see brand-name drug makers selling their biologics under as structure similar to that used for authorized generics.
Overcoming Challenges to Improve Access and Reduce Costs
November 12th 2024Biosimilars hold the potential to dramatically lower health care costs and improve access to life-changing treatments, but realizing this potential will require urgent policy reforms, market competition, and better education for both providers and patients.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Skyrizi Overtakes Humira: “Product Hopping” Leaves Biosimilar Market in Limbo
November 7th 2024For the first time, Skyrizi (risankizumab-rzaa) has replaced Humira (reference adalimumab) as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Panelists Stress Stakeholder Education to Build Confidence in Biosimilars
October 31st 2024By expanding educational initiatives to clarify biosimilar safety, efficacy, and interchangeability, stakeholders can foster trust, improve access, and ensure that biosimilars are widely accepted as high-quality, cost-effective alternatives to originator biologics.